Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro, Inc. develops and commercializes medical-device and therapy-enabling systems for precise navigation to the brain and spine. Its recurring news includes updates on the FDA-cleared and CE-marked ClearPoint Neuro Navigation System, SmartFrame navigation platform, SmartFlow Neuro Cannula, Velocity Alpha MR High Speed Surgical Drill System, and services that support controlled CNS delivery for cell and gene therapy programs.
Company announcements also cover financial results, product clearances and international regulatory approvals, preclinical development services, biopharma and academic partnerships, and integration of the completed IRRAS Holdings acquisition, which expanded the portfolio into neurocritical care and IRRAflow-related products.
ClearPoint Neuro (CLPT) announced a worldwide license and research agreement with Philips to develop the ‘Maestro™’ Brain Model, set for launch in 2022. This collaboration aims to enhance various applications in drug delivery, deep brain stimulation, laser ablation, and biopsies, enabling precise treatment paths and safer procedures. Philips' Brain Model technology, developed over 10 years, offers accurate assessments backed by extensive research. ClearPoint’s products are FDA cleared and used in over 60 clinical sites across the U.S., Canada, and Europe, supporting a diverse range of neurological therapies.
ClearPoint Neuro has announced a partnership with Blackrock Microsystems to develop innovative products in the neurosurgery market. This collaboration is set to tap into a combined addressable market exceeding $100 million. The first product, the Microelectric Recording (MER) platform, is expected to launch in 2023, followed by advanced biopsy needles and other neural electrodes. This strategic alliance combines ClearPoint's navigation expertise and Blackrock's precision electrode technology, aiming to enhance patient outcomes in neurosurgery.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the appointment of R. John Fletcher as Chairman of the Board, succeeding Kimble L. Jenkins, who retired to focus on his CEO role at OrthoSouth. Joe Burnett, CEO of ClearPoint, praised Jenkins for his contributions in growing the company. Fletcher, recognized for his leadership during Spectranetics' acquisition by Philips for $2.2 billion, aims to guide ClearPoint in its next growth phase. The company continues to advance its neurosurgery solutions, including FDA-cleared products for complex neurological disorders.
ClearPoint Neuro (Nasdaq: CLPT) announced the appointment of Ernesto Salegio, PhD, as Vice President, Segment Leader of Translational and Pre-Clinical Research, starting March 1, 2021. Dr. Salegio has over 19 years of experience in translational neuroscience, specializing in gene therapy delivery. He will enhance ClearPoint’s Biologics and Drug Delivery team, established in 2020, aimed at supporting pharmaceutical partners with pre-clinical services. ClearPoint aims to provide comprehensive medical device solutions for gene and stem cell therapies to improve patient care.
ClearPoint Neuro (Nasdaq: CLPT) has successfully implemented its Version 2.0 software along with the ClearPoint Navigation System at Rigshospitalet, Copenhagen, marking the first usage in Europe. This procedure utilized live MRI guidance for laser catheter navigation, showcasing the system's enhanced precision. Dr. Rune Rasmussen emphasized its superior accuracy compared to traditional methods. ClearPoint aims to expand its presence in Europe, attracting more partners for clinical trials and increasing its service reach across the EMEA region.
ClearPoint Neuro (CLPT) reported preliminary unaudited revenue of approximately $3.7 million for Q4 2020, marking a 14% increase year-over-year, while full-year 2020 revenue is estimated at $12.8 million, also a 14% growth. The company supported 175 cases in Q4 amid ongoing COVID-19 disruptions. Cash used in operations was approximately $2.4 million in Q4 and $7.9 million for the full year, with cash and cash equivalents at $20.1 million as of December 31, 2020.
CEO Joe Burnett noted challenges posed by COVID-19, anticipating ongoing pressures on elective procedures into the first half of 2021.
ClearPoint Neuro (Nasdaq: CLPT) announced a $7.5 million strategic investment from Petrichor Healthcare Capital Management, amending their January 2020 financing agreement. The new terms include a conversion price increase from $6.00 to $10.14 per share and a reduced interest rate of 7%, down from 9%. The funds will support global product commercialization, strategic partnerships, and R&D. The company expects to enter 2021 with cash balances exceeding $20 million, positioning itself for growth in next-generation therapies.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced a significant milestone with the completion of its 4,000th neurosurgical procedure using the ClearPoint Neuro Navigation System at Dartmouth-Hitchcock Medical Center. This advanced MRI-guided technology is now utilized at 60 leading neurosurgical centers in the US for procedures like deep brain stimulation and biopsies. ClearPoint's mission focuses on improving patient outcomes for complex neurological disorders, supported by a team of clinical specialists and partnerships with biologics and drug delivery companies.
ClearPoint Neuro reported a record revenue of $3.5 million for Q3 2020, reflecting a 20% increase year-over-year. The increase was fueled by a 162% rise in biologics and drug delivery revenue, totaling $1.5 million, thanks to new clinical service relationships. However, functional neurosurgery navigation revenue fell 1% to $1.8 million, and capital equipment revenue dropped 48% to $0.2 million. Operating expenses surged by 43% to $4.1 million, leading to an operating loss of $1.3 million. Cash reserves stood at $14.7 million as of September 30, 2020.
ClearPoint Neuro (Nasdaq: CLPT) will release its 2020 third quarter financial results on November 10, 2020, after market close. A conference call to discuss the results will follow at 4:30 p.m. Eastern. Interested participants can join via phone or through a live webcast on the company's website. ClearPoint Neuro focuses on improving therapies for neurological disorders with its FDA-cleared ClearPoint® Neuro Navigation System, currently installed in 60 clinical sites. Risks include uncertainties related to COVID-19 and future revenue generation from its products.